Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
270 USD | +0,22% | +0,39% | -6,26% |
Attività
- vendite di farmaci (94,2%): farmaci per il trattamento di tumori, disturbi metabolici, malattie ossee, insufficienza renale, emofilia, ecc;
- altro (5,8%): principalmente royalties.
Gli Stati Uniti rappresentano il 70,3% delle vendite nette.
Numero di dipendenti: 26 700
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Human Therapeutics
95,5
%
| 24 801 | 94,2 % | 26 910 | 95,5 % | +8,50% |
Other
4,5
%
| 1 522 | 5,8 % | 1 280 | 4,5 % | -15,90% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
70,3
%
| 18 595 | 70,6 % | 19 806 | 70,3 % | +6,51% |
Rest of World
29,6
%
| 7 655 | 29,1 % | 8 337 | 29,6 % | +8,91% |
Canada
0,2
%
| 73 | 0,3 % | 47 | 0,2 % | -35,62% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/10/19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
Chief Tech/Sci/R&D Officer | 53 | - | |
Esteban Santos
COO | Chief Operating Officer | 56 | 01/01/07 |
Nancy Grygiel
CMP | Compliance Officer | 56 | 01/01/15 |
Mike Zahigian
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/01 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/01/05 |
Darryl Sleep
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/18 |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/06/23 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/02/17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/10/16 |
Robert Williams
BRD | Director/Board Member | 75 | 17/10/14 |
Robert Eckert
BRD | Director/Board Member | 69 | 01/01/03 |
Ronald Sugar
BRD | Director/Board Member | 75 | 22/07/10 |
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/06 |
Wanda Austin
BRD | Director/Board Member | 69 | 24/10/17 |
Tyler Jacks
BRD | Director/Board Member | 63 | 01/01/12 |
Omar Ishrak
BRD | Director/Board Member | 68 | 30/07/21 |
Greg Garland
BRD | Director/Board Member | 66 | 16/10/13 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 536 375 548 | 535 025 126 ( 99,75 %) | 0 | 99,75 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
BEIGENE, LTD. 19.82% | 246 269 426 | 19.82% | 2 992 444 422 $ |
NEUMORA THERAPEUTICS, INC. 22.26% | 35 368 653 | 22.26% | 486 318 979 $ |
4 910 000 | 5.50% | 116 121 500 $ | |
VIGIL NEUROSCIENCE, INC. 8.69% | 3 206 281 | 8.69% | 10 933 418 $ |
100 993 | 0.67% | 2 965 154 $ |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the private company is Gabor Sztaniszlav. |
Pharmaceuticals: Major
|
Amgen Technology Ltd.
Amgen Technology Ltd. BiotechnologyHealth Technology Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The private company is located in Bermuda. |
Biotechnology
|
Amgen Manufacturing Ltd. (Bermuda)
|
Settore
Vendite per attività
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-6,26% | 145 Mrd | |
+25,83% | 661 Mrd | |
+27,00% | 566 Mrd | |
-6,76% | 352 Mrd | |
+20,34% | 332 Mrd | |
+3,00% | 283 Mrd | |
+13,09% | 231 Mrd | |
+5,46% | 200 Mrd | |
-9,61% | 195 Mrd | |
-11,77% | 144 Mrd |
- Borsa valori
- Azioni
- Azione AMGN
- Società Amgen Inc.